Supplementary figure 1 Paul et al.



**D**




**COPR5 is involved in myogenic differentiation**

A) Higher panel : Phase contrast micrographs of C2C12 cells transduced with viral particles encoding two other anti-*COPR5* shRNAs (2 and 3). Comparison with the shRNA 1 used in Fig.1*a* is shown at day 3 (D3) of differentiation. Lower panel : Expression analysis of *COPR5* and Myosin Heavy Chain (*MHC*) expression was assessed by RT-qPCR using RNAs isolated from these different transduced cells. Results were normalized to those of S26 RNA and values expressed as a fold change compared to control represent the means +/- standard deviation of three independent analysis.

B) Phase contrast micrographs of C2C12 cells transduced with a *PRMT5* shRNA encoding viral particles (higher panel). Analysis of expression levels of *MHC* and *PRMT5* was performed at day D3 of differentiation as in (A) and is shown in the lower panel.

C) Merge images of immunofluorescence analysis using Image J software of sh*LUC* and sh*COPR5* C2C12 cells at confluency and in differentiating conditions after DAPI staining and anti-MHC antibody labelling are shown.

D) Left panel: Phase contrast micrographs of C2C12 cells transduced with HA-*COPR5* encoding viral particles was compared to control (CTL) at confluency (D0), days 1 (D1) and 3 (D3) of differentiation, and after three days post confluency in growth medium (ND03). Upper right panel: Myosin Heavy Chain (*MHC*) expression was assessed by RT-qPCR as in (A) at the indicated time point in CTL and HA-COPR5 expressing cells. Lower right panels: Protein extracts from either CTL or HA-COPR5 expressing cells were recovered and analyzed by western blotting using antibodies raised against MHC, HA(COPR5) and GAPDH for normalization.